骨髓增生异常综合征骨髓组织中类胰酶阳性肥大细胞水平的研究

目的:探讨骨髓增生异常综合征(MDS)患者骨髓组织中类胰酶阳性的肥大细胞表达水平.方法:用骨髓塑料冷包埋技术结合免疫组织化学的方法检测10例健康供者,8例IDA患者、20例MDS(11例低危组,9例高危组)、17例急性髓性白血病(AML)患者骨髓类胰酶阳性的肥大细胞的数量,并作对比分析.结果:IDA组(63.43±44.29)与健康供者的类胰酶阳性肥大细胞数(61.43±56.19)类似(P值>0.05).MDS组(195.95±117.39)较健康供者类胰酶阳性的肥大细胞数增多(P值<0.05).MDS高危组(229.25±139.68)较低危组(171.73±98.07)高,但无统计学差异(P值>0.05));AML组(608.44±342.58)较MDS组明显增多(P值<0.01).各组类胰酶阳性肥大细胞数与外周血常规、骨髓原始粒细胞数、嗜酸性粒细胞数、嗜碱性粒细胞数无相关性.结论:MDS和AML患者骨髓组织中均存在类胰酶阳性肥大细胞数目异常增多现象,它可能在MDS的病理发生发展中起一定作用.

The expression level of tryptase-positive mast cells in the bone marrow of MDS patients

Objective:To explore the level of tryptase-positive mast cells in the bone marrow of MDS patients. Methods:Bone marrow biopsies from 10 healthy controls,8 IDA,20 myelodysplastic syndrome and 17 acute myeloid leukemias were embedded in cold plastic resin. Immunohistochemical method was used to show the number of tryptase-positive cells.The level of tryptase-positive cells were compared. Results:No difference was found between the level of tryptase-positive mast cells in IDA group(63.43 ± 44.29) and healthy group(61.43 ± 56.19)(P > 0.05);the level in MDS group(195.95 ± 117.39) was higher than that in control group(P < 0.05), high risk group(229.25 ± 139.68) was higher than low risk group(171.73 ± 98.07),but the difference was not significant(P > 0.05). AML group(608.44 ± 342.58) was higher than that of MDS group(P < 0.01). Conclusion:The number of tryptase-positive mast cells in the bone marrow of MDS patients was increased and may play a role in the pathogenesis and development of the disease.